News

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications.

As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems designed to enhance human performance in virtual and mixed reality environments. With this collaboration, 3Waves has developed a proprietary vestibular interface platform capable of translating inputs from VR/XR simulators into true physical sensations, creating virtual motion.

“We believe the future of immersive technology is a full sensory coherence between the digital environment and human perception. 3Waves represents a major step towards that future by enabling direct vestibular integration with virtual environments to create virtual motion,” said David Remer, Head of Engineering at 3Waves. “We see this as the missing physiological interface layer that has, in many ways, limited XR adoption for years. We are excited to advance that capability and bring it into commercial markets.”

Luna Labs’ efforts on 3Waves technology is part of a broader strategy that is focused on transitioning high potential technologies into scalable standalone businesses positioned for long term growth. “Starting 3Waves is a great example of the Luna Labs commercialization model. This technology started with Phase I SBIR funding, matured with a Phase III contract and internal resources, and we are now positioning it to stand on its own,” said James Garrett, CEO of Luna Labs.

Read more here.

Recent News

10/26/2026

ATCC Selected by ARPA-H to Support Next-Generation BioStabilization Technologies

ATCC has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an affiliate to provide independent verification and validation (IV&V) for its BioStabilization Systems (BoSS) program. Through this program, BoSS is taking the “200-degree leap,” from -196°C toward room temperature, to make life-saving cell therapies as easy to store and ship as …

10/26/2026

Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing treatments for serious inflammatory diseases, today announced that Celia Economides, the Company’s current Executive Vice President of Finance, is expected to be appointed Chief Financial Officer effective promptly after the Company’s reconvened 2026 Annual Meeting of Stockholders, if certain …

10/23/2026

PAK BioSolutions and iBET Advance Integrated Continuous AAV8 Purification

PAK BioSolutions today announced the publication of a peer-reviewed study on integrated, continuous purification of adeno-associated virus serotype 8 (AAV8) using the PAK PD™ Process Development Scale Continuous Purification System. Conducted in collaboration with iBET – Instituto de Biologia Experimental e Tecnológica, the study, “Streamlining AAV8 Purification with Cyclic Integrated Capture–Polishing Chromatography,” was published in …